New research published in The Lancet Regional Health Americas found that adherence to diabetes screening guidelines is sub-optimal, especially among young males. Despite lower rates of adherence to screening, males have higher rates of prediabetes and diabetes compared to females. This paper is the first publications from them Real-world Evidence on the Association Between Diabetes […]
We are pleased to share the 2021 CVC annual report! This year’s theme, Global Vision ⟷ Local Action, highlights a variety of the CVC’s activities that have started at a global or national scale and have subsequently translated into local initiatives. The theme also reflects our organization’s aim to bring people from different places together in the […]
The SODIUM-HF trial was presented during the Late-Breaking Clinical Trial session at the American College of Cardiology in Washington, DC on April 02, 2022, and a simultaneously published in The Lancet Journal. The SODIUM-HF study examined the effects of a low-salt diet compared to usual dietary recommendations for people with heart failure. The trial took place […]
The New Trends in Fibrinolysis symposium, sponsored by Boehinger Ingelheim, took place virtually on August 28th as part of the 2021 ESC Congress. Chaired by CVC Founding Director Dr. Paul Armstrong, the session sought to: Recognize the challenges in STEMI care, particularly in reducing ischaemic time and establishing STEMI networks. Apply given strategies to overcome […]
“We build too many walls and not enough bridges.” -Isaac Newton While the pandemic walled us in physically, the CVC continued to build virtual bridges to improve our understanding of cardiovascular disease. Accordingly, the theme of our 2020 CVC annual report is ‘Bridging the Gap‘ and it collates some of the key advances engineered in part […]
The CVC is proud to congratulate co-director Dr. Padma Kaul on her recent appointment as the Heart & Stroke Chair in Cardiovascular Research. As per the University of Alberta announcement, In her role as Heart & Stroke Chair in Cardiovascular Research, Dr. Kaul will be responsible for being a leader in the development of cardiovascular […]
Vericiguat is the first soluble guanylate cyclase stimulator approved to treat heart failure.
New Research published in Circulation suggests that women are at greater risk than men of dying or developing heart failure in the five years following their first severe heart attack. The study also found that at the time of their heart attacks women were typically older and more likely to have complicated medical histories. For […]
A new research story on BeTheCure.ca highlights Deborah McLeod’s experience as a participant in the VICTORIA trial, and the important discoveries that have been made about vericiguat and its impact on patients with heart failure. To learn more about Deborah’s story and the vital role patient participation has in clinical research, view the blog post here: bethecure.ca/stories/deborah/
The CVC is proud to recognize that Dr. Justin Ezekowitz has been elected as a Fellow of the Canadian Academy of Health Sciences (CAHS). Election to the CAHS Fellowship is considered one of the highest honours for individuals in the Canadian health sciences community. Fellows have demonstrated, through their careers and lives, that they are […]
